{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-165406","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2023-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.015342+00:00","generated_at":"2026-06-14T03:12:24.832143+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Coya CEO update: ALS POC shows disease halted 24wks; AD Phase2 data due Q2 2024","bullets":["COYA 302 in ALS: disease progression halted to week 24 with minimal decline to week 48 on ALSFRS scale in open-label study.","COYA 301 in AD: cognitive function improved or stabilized; Treg function enhanced, cytokines reduced, neuroinflammation decreased.","Pre-IND meeting with FDA for COYA 302 planned fall 2023; IND submission early 2024 with Phase 2 trial to follow.","Academic double-blind Phase 2 trial of low-dose IL-2 in AD (funded by Gates Foundation) top-line data expected Q2 2024.","Appointed immunologist Dr. Guillaume Dorothee to SAB; hired Arun Swaminathan as business development executive."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-165406","json":"https://secwatch.observer/filing/0001193125-23-165406.json","markdown":"https://secwatch.observer/filing/0001193125-23-165406.md","text":"https://secwatch.observer/filing/0001193125-23-165406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312523165406/0001193125-23-165406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312523165406/d514893d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T03:12:24.832143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}